inhibitor

(redirected from dipeptidyl peptidase-4 inhibitor)
Also found in: Dictionary, Medical, Legal, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Antonyms for inhibitor

a substance that retards or stops an activity

References in periodicals archive ?
Effect of glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non alcoholic fatty liver disease.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled parallel group study.
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Effects of clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus.
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
NESINA, a dipeptidyl peptidase-4 inhibitor (DPP-4i), is aimed at decreasing the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study In adult patients with type 2 diabetes.
The injectable incretinomimetic exenatide, the injectable amylinomimetic pramlintide, and the dipeptidyl peptidase-4 inhibitor sitagliptin provide additional options for physicians in diabetes-modifying therapy.
Major Finding: Patients on a dipeptidyl peptidase-4 inhibitor to treat their type 2 diabetes had a 49% reduction in the composite endpoint of cardiovascular death, MI, or stroke compared with those in the comparator arm in a large meta-analysis.
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitaglipim as monotherapy over 12 weeks in patients with type 2 diabetes.
Full browser ?